Home Clinical Topics FDA recommends removing Avastin's breast cancer indication

FDA recommends removing Avastin’s breast cancer indication

The U.S. Food and Drug Administration (FDA) is recommending that the breast cancer indication for Avastin be removed from its label “because the drug has not been shown to be safe and effective for that use.” Read more here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here